{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '9.6.', 'Study Drug (Investigational Medicinal Product) Accountability', '52', '9.7.', 'Concomitant Medications', '52', '9.7.1.', 'Prohibited Medications', '53', '10.', 'STUDY CONDUCT', '53', '10.1.', 'Overview', '53', '10.2.', 'Schedule of Assessments', '54', '10.3.', 'Study Visits', '63', '10.3.1.', 'Screening Visit', '63', '10.3.2.', 'Period Between Screening and Baseline', '64', '10.3.3.', 'Part 1', '66', '10.3.3.1.', 'Baseline Visit (Day 1)', '66', '10.3.3.2.', 'Week 2 Visit', '67', '10.3.3.3.', 'Week 4, 8, 12, and 18 Visits', '67', '10.3.3.4.', 'Week 24 Visit', '68', '10.3.4.', 'Part 2', '69', '10.3.4.1.', 'Week 26 Visit', '69', '10.3.4.2.', 'Week 28, 32, 36, 48, and 52 Visits', '69', '10.3.4.3.', 'Week 40 and 44 Phone Calls', '70', '10.3.5.', 'Part 3', '70', '10.3.5.1.', 'Week 60, 72, 84, 96, and 104 Visits', '70', '10.3.5.2.', 'Week 56, 64, 68, 76, 80, 88, 92, and 100 Phone Calls', '71', '10.3.5.3.', 'End-of-Study/Early Termination Visit', '71', '11.', 'ASSESSMENTS', '72', '11.1.', 'Chronology of Assessments', '72', '11.2.', 'Investigator-Completed Assessments', '72', '11.2.1.', 'HAE Medical and Medication History', '73', '11.2.2.', 'Physical Examination', '73', '11.2.3.', 'Weight/Body Mass Index', '73', '11.2.4.', '12-lead Electrocardiograms', '73', '11.2.5.', 'Vital Signs', '74', '11.2.6.', 'Clinical Laboratory Evaluations', '74', '11.2.7.', 'Screening for Human Immunodeficiency Virus, Hepatitis B, and Hepatitis C', 'Serology', '76', '19']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '11.2.8.', 'HLA Typing', '76', '11.2.9.', 'Pregnancy Testing', '76', '11.2.10.', 'HAE Diagnostic Confirmation', '76', '11.2.11.', 'Other Laboratory Assessments', '77', '11.2.12.', 'Pharmacokinetics and Pharmacodynamics', '77', '11.2.13.', 'Pharmacogenomic Testing', '77', '11.2.14.', 'Rash Assessment', '78', '11.2.15.', 'Adverse Events', '79', '11.3.', 'Patient-Reported Outcomes', '79', '11.4.', 'Angioedema Events and Dosing e-Diary, Investigator Event Follow-up and', 'Confirmation', '80', '11.4.1.', 'Screening and Parts 1 and 2', '81', '11.4.1.1.', 'Investigator Follow-up of Angioedema Events and Expert Confirmation of', 'Angioedema Events', '81', '11.4.1.2.', 'Scheduled Telephone Contact', '82', '11.4.2.', 'Part 3', '82', '11.4.2.1.', 'Confirmation of Angioedema Events', '82', '11.4.2.2.', 'Scheduled Telephone Contact', '83', '12.', 'ADVERSE EVENT MANAGEMENT AND REPORTING', '83', '12.1.', 'Adverse Events', '83', '12.1.1.', 'Definitions', '83', '12.1.1.1.', 'Adverse Event', '83', '12.1.1.2.', 'Serious Adverse Event', '84', '12.1.1.3.', 'Adverse Events of Special Interest', '85', '12.1.2.', 'Method, Frequency, and Time Period for Detecting Adverse Events and', 'Reporting Serious Adverse Events', '85', '12.1.3.', 'Definition of Severity', '86', '12.1.4.', 'Definition of Relationship to Study Drug', '86', '12.1.5.', 'Reporting Serious Adverse Events and Suspected Unexpected Serious', 'Adverse Reactions', '87', '12.1.5.1.', 'Reporting Adverse Events of Special Interest', '88', '12.1.6.', 'Pregnancy', '89', '12.1.7.', 'Serious Breaches of Good Clinical Practice', '89', '12.1.8.', 'Treatment Interruptions', '89', '20']\n\n###\n\n", "completion": "END"}